SCHEMBL4077006

SCHEMBL4077006

Cn1cc2c(cc1=O)C1(CCN(Cc3ccc(/C(=N/OCC4(O)CC4)c4ccc(F)c(F)c4)nc3)CC1)OC2

nearest known ligand 0.86

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 16/20 0.86
KCNH2 Q12809 11/20 0.86
ADRA1A P35348 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4075283 1.00 MCHR1 (0.86) MCHR1KCNH2ADRA1A
SCHEMBL4075293 1.00 MCHR1 (0.86) MCHR1KCNH2ADRA1A
SCHEMBL4068858 0.92 MCHR1 (1.00) MCHR1KCNH2ADRA1A
SCHEMBL4067114 0.92 MCHR1 (0.89) MCHR1KCNH2ADRA1A
SCHEMBL4066961 0.92 MCHR1 (1.00) MCHR1KCNH2ADRA1A
SCHEMBL4067107 0.92 MCHR1 (0.89) MCHR1KCNH2ADRA1A
SCHEMBL4066972 0.92 MCHR1 (1.00) MCHR1KCNH2ADRA1A
SCHEMBL4068701 0.91 MCHR1 (0.86) MCHR1KCNH2ADRA1A
SCHEMBL4065636 0.91 MCHR1 (0.86) MCHR1KCNH2ADRA1A
SCHEMBL4068689 0.91 MCHR1 (0.86) MCHR1KCNH2ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247560-A1 Diaryl ketimine derivative BANYU PHARMACEUTICAL CO., LTD. 2009-10-01 US disclosed
EP-2072519-A1 DIARYL KETIMINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247560-A1 Diaryl ketimine derivative NR0B2, NR2C2, NR3C2 MCHR1 730/4885KCNH2 296/4885ADRA1A 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.